Inhibition of C1q-β-amyloid binding protects hippocampal cells against complement mediated toxicity

Journal of Neuroimmunology

Volumn 137, Issue 1-2, 2003, Pages 12-18

  Sarvari M ^a   Vago I ^a   Weber C S ^a   Nagy, J ^a   Gal P ^b   Mak M ^a   Kosa J P ^a   Zavodszky P ^b   Pazmany T ^a,c  

^a GEDEON RICHTER LTD   (Hungary)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Alzheimer's disease; C1q; Complement system; amyloid

Indexed keywords

AMYLOID BETA PROTEIN; COMPLEMENT COMPONENT C1Q; PROTEIN INHIBITOR;

ANIMAL CELL; ARTICLE; BINDING SITE; BRAIN NERVE CELL; CELL CULTURE; CELL PROTECTION; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; DRUG MECHANISM; HIPPOCAMPUS; LYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; RAT;

EID: 17544395986     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(03)00040-7     Document Type: Article

References (38)

1. Bradt B., Kolb W.P., Cooper N.R. Complement-dependent proinflammatory properties of the Alzheimer's disease β-peptide. J. Exp. Med. 188:1998;431-438.
2. Chen S., Frederickson C.A., Brunden K.R. Neuroglial-mediated immuno-inflammatory responses in Alzheimer's disease: complement activation and therapeutic approaches. Neurobiol. Aging. 17:1996;781-787.
3. Davoust N., Nataf S., Reiman R., Holers M.V., Campbell I.L., Barnum S.C. Central nervous system-targeted expression of the complement inhibitor sCrry prevents experimental allergic encephalomyelitis. J. Immunol. 163:1999;6551-6556.
4. Eikelenboom P., Stam F.C. Immunoglobulins and complement factors in senile plaques. Acta Neuropathol. 57:1982;239-242.
5. Frank M.M., Fries L.F. The role of complement in inflammation and phagocytosis. Immunol. Today. 12:1991;322-326.
6. Gasque P., Dean Y.D., McGreal E.P., VanBeek J., Morgan B.P. Complement components of the innate immune system in health and disease in the CNS. Immunopharmacology. 49:2000;171-186.
7. Gewurz H., Ying S., Jiang H., Lint T.F. Nonimmune activation of the classical complement pathway. Behring-Inst.-Mitt. 93:1993;138-147.
8. Hjelmström P., Juedes A.E., Fjell J., Ruddle N.H. B cell-deficient mice develop experimental allergic encephalomyelitis with demyelination after myelin oligodendrocyte glycoprotein sensitization. J. Immunol. 161:1998;4480-4483.
9. Itagaki S., Akiyama H., Saito H., McGeer P.L. Ultrastructural localization of complement membrane attack complex (MAC)-like immunoreactivity in brains of patients with Alzheimer's disease. Brain Res. 645:1994;78-84.
10. Jiang H., Robey F.A., Gewurz H. Localization of sites through which CRP binds and activates complement to residues 14-26 and 76-92 of the human C1q A chain. J. Exp. Med. 175:1992;1373-1379.
11. Jiang H., Burdick D., Glabe C.G., Cotman C.W., Tenner A.J. B-amyloid activates complement by binding to a specific region of the collagen-like domain of the C1q A chain. J. Immunol. 152:1994;5050-5059.
12. Johns T.G., Bernard C.C.A. Binding of complement component C1q to myelin oligo-dendrocyte glycoprotein: a novel mechanism for regulating CNS inflammation. Mol. Immunol. 34:1997;33-38.
13. Kishore U., Reid K.B.M. C1q: structure, function, and receptors. Immunopharmacology. 49:2000;159-170.
14. McGeer P.L., McGeer E.G. Inflammation, autotoxicity and Alzheimer disease. Neurobiol. Aging. 22:2001;799-809.
15. Müller-Eberhard H. Molecular organization and function of the complement system. Annu. Rev. Biochem. 57:1987;321-347.
16. O'Barr S., Cooper N.R. The C5a complement activation peptide increases IL-1beta and IL-6 release from amyloid-beta primed human monocytes: implications for Alzheimer's disease. J. Neuroimmunol. 109:2000;87-94.
17. Pazmany T., Kosa J.P., Tomasi T.B., Mechtler L., Turoczi A., Lehotzky A. Effect of transforming growth factor-β1 on microglial MHC-class II expression. J. Neuroimmunol. 103:2000;122-130.
18. Reid K.B.M., Porter R.R. Subunit composition and structure of subcomponent C1q of the first component of human complement. Biochem. J. 155:1976;19-23.
19. Rogers J., Cooper N.R., Webster S., Schultz J., McGeer P.L., Styren S.D., Civin W.H., Brachova L., Bradt B., Ward P., Lieberburg I. Complement activation by β-amyloid in Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 89:1992;10016-10020.
20. Sahu A., Lambris J.D. Complement inhibitors: a resurgent concept in anti-inflammatory therapeutics. Immunopharmacology. 49:2000;133-148.
21. Schultz J., Schaller J., McKinley M., Bradt B., Cooper N.R., May P., Rogers J. Enhanced cytotoxicity of amyloid β-peptide by a complement dependent mechanism. Neurosci. Lett. 175:1994;99-102.
22. Schumaker V.N., Zavodszky P., Poon P.H. Activation of the first component of complement. Annu. Rev. Immunol. 5:1987;21-42.
23. Singhrao S.K., Neal J.W., Rushmere N.K., Morgan B.P., Gasque P. Spontaneous classical pathway activation and deficiency of membrane regulators render human neurons susceptible to complement lysis. Am. J. Pathol. 157:2000;905-918.
24. Skribanek Z., Balaspiri L., Mak M. Interaction between synthetic amyloid-β-peptide (1-40) and its aggregation inhibitors studied by electrospray ionization mass spectrometry. J. Mass Spectrom. 36:2001;1226-1229.
25. Stoltzner S.E., Grenfell T.J., Mori C., Wisniewski K.E., Wisniewski T.M., Selkoe D.J., Lemere C.E. Temporal accrual of complement proteins in amyloid plaques in Down's syndrome with Alzheimer's disease. Am. J. Pathol. 156:2000;489-499.
26. Tacnet-Delorme P., Chevallier S., Arlaud G.J. Beta-amyloid fibrils activate the C1 complex of complement under physiological conditions: evidence for a binding site for A beta on the C1q globular region. J. Immunol. 167:2001;6374-6381.
27. Tennent G.A., Lovat L.B., Pepys M.B. Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. Proc. Natl. Acad. Sci. U. S. A. 92:1995;4299-4303.
28. Uwatoko S., Mannik M. The location of binding sites on C1q for DNA. J. Immunol. 144:1990;3484-3488.
29. Vanguri P., Shin M.L. Activation of complement by myelin: Identification of C1q binding proteins of human myelin from the central nervous tissue. J. Neurochem. 46:1986;1535-1541.
30. Veerhuis R., Janssen I., De Groot C.J.A., Van Muiswinkel F.L., Hack C.E., Eikelenboom P. Cytokines associated with amyloid plaques in Alzheimer's disease brain stimulate human glial and neuronal cultures to secrete early complement proteins, but not C1-Inhibitor. Exp. Neurol. 160:1999;289-299.
31. Velazquez P., Cribbs D.H., Poulos T.L., Tenner A.J. Aspartate residue 7 in amyloid β-protein is critical for classical complement pathway activation: implications for Alzheimer's disease pathogenesis. Nat. Med. 3:1997;77-79.
32. Webster S., O'Barr S., Rogers J. Enhanced aggregation and β structure of amyloid β peptide after co-incubation with C1q. J. Neurosci. Res. 39:1994;448-456.
33. Webster S., Lue L.F., Brachova L., Tenner A.J., McGeer P.L., Terai K., Walker D.G., Bradt B., Cooper N.R., Rogers J. Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer's disease. Neurobiol. Aging. 18:1997;415-421.
34. Webster S., Yang A.J., Margol L., Garzon-Rodriguez W., Glabe C.G., Tenner A.J. Complement component C1qmodulates the phagocytosis of Aβ by microglia. Exp. Neurol. 161:2000;127-138.
35. Yang B., Li R., Meri S., Rogers J., Shen Y. Deficiency of complement defense protein CD59 may contribute to neurodegeneration in Alzheimer's disease. J. Neurosci. 20:2000;7505-7509.
36. Yasojima K., Schwab C., McGeer E.G., McGeer P.L. Up-regulated production and activation of the complement system in Alzheimer's disease brain. Am. J. Pathol. 154:1999;927-936.
37. Ying S.C., Gewurz A.T., Jiang H., Gewurz H. Human serum amyloid P component oligomers bind and activate the classical complement pathway via residues 14-26 and 76-92 of the A chain collagen-like region of C1q. J. Immunol. 150:1993;169-176.
38. Zahedi K. Characterization of the binding of serum amyloid P to type IV collagen. J. Biol. Chem. 271:1996;14897-14902.